mimedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. the company processes the human placental tissue utilizing its proprietary purion® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. mimedx has supplied more than two million allografts, through both direct and consignment shipments. for additional information, please visit www.mimedx.com.
Company profile
Ticker
MDXG
Exchange
Website
CEO
Timothy R. Wright
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Alynx, Co.
SEC CIK
Corporate docs
Subsidiaries
MiMedx Tissue Services, LLC • MiMedx Processing Services, LLC • MiMedx Supply, LLC ...
IRS number
900300868
MDXG stock data
Latest filings (excl ownership)
8-K
MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA
27 Mar 24
8-K
MIMEDX Announces Appointment of Two New Independent Directors
4 Mar 24
8-K
MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
MIMEDX Announces Improved Capital Structure with New Senior
22 Jan 24
8-K
MIMEDX Announces Conversion of Outstanding Series B Convertible Preferred Stock to Common Stock
28 Dec 23
8-K
MIMEDX to Participate in Upcoming Investor Conferences
13 Nov 23
10-Q
2023 Q3
Quarterly report
30 Oct 23
8-K
MIMEDX Announces Third Quarter 2023 Operating and Financial Results
30 Oct 23
8-K
Departure of Directors or Certain Officers
5 Sep 23
Transcripts
MDXG
Earnings call transcript
2023 Q4
28 Feb 24
MDXG
Earnings call transcript
2023 Q3
30 Oct 23
MDXG
Earnings call transcript
2023 Q2
1 Aug 23
MDXG
Earnings call transcript
2023 Q1
2 May 23
MDXG
Earnings call transcript
2022 Q4
28 Feb 23
MDXG
Earnings call transcript
2022 Q3
2 Nov 22
MDXG
Earnings call transcript
2022 Q2
3 Aug 22
MDXG
Earnings call transcript
2022 Q1
4 May 22
MDXG
Earnings call transcript
2021 Q4
1 Mar 22
MDXG
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
4
William Frank IV Hulse
10 Apr 24
3
DOROTHY E PUHY
18 Mar 24
3
Tiffany Olson
18 Mar 24
4
William Frank IV Hulse
15 Mar 24
4
William Frank IV Hulse
5 Mar 24
4
Ricci S Whitlow
5 Mar 24
4
RICE DOUG
5 Mar 24
4
Ricci S Whitlow
21 Feb 24
144
Notice of proposed sale of securities
20 Feb 24
144
Notice of proposed sale of securities
16 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
43.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 185 |
Opened positions | 30 |
Closed positions | 22 |
Increased positions | 69 |
Reduced positions | 42 |
13F shares | Current |
---|---|
Total value | 407.52 bn |
Total shares | 63.96 mm |
Total puts | 78.30 k |
Total calls | 99.90 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 8.94 mm | $65.16 bn |
Prescience Investment | 7.60 mm | $0.00 |
Vanguard | 6.44 mm | $46.93 bn |
STT State Street | 4.13 mm | $30.10 bn |
Paradigm Capital Management | 3.48 mm | $25.37 bn |
Geode Capital Management | 2.43 mm | $17.70 bn |
Cannell Capital | 2.27 mm | $16.58 bn |
MS Morgan Stanley | 1.58 mm | $11.50 bn |
Richmond Brothers | 1.48 mm | $10.80 bn |
Renaissance Technologies | 1.08 mm | $7.88 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Apr 24 | William Frank IV Hulse | Common Stock | Payment of exercise | Dispose F | No | No | 6.9 | 8,896 | 61.38 k | 471,063 |
13 Mar 24 | William Frank IV Hulse | Common Stock | Sell | Dispose S | No | No | 7.95 | 20,381 | 162.03 k | 479,959 |
4 Mar 24 | William Frank IV Hulse | Common Stock | Payment of exercise | Dispose F | No | No | 8.26 | 15,351 | 126.80 k | 500,340 |
1 Mar 24 | William Frank IV Hulse | Common Stock | Grant | Acquire A | No | No | 0 | 59,127 | 0.00 | 515,691 |
1 Mar 24 | William Frank IV Hulse | Stock Options Common Stock | Grant | Acquire A | No | No | 8.63 | 71,541 | 617.40 k | 71,541 |
1 Mar 24 | Whitlow Ricci S | Common Stock | Grant | Acquire A | No | No | 0 | 58,478 | 0.00 | 459,528 |
1 Mar 24 | Whitlow Ricci S | Stock Options Common Stock | Grant | Acquire A | No | No | 8.63 | 70,755 | 610.62 k | 70,755 |
1 Mar 24 | Doug Rice | Common Stock | Grant | Acquire A | No | No | 0 | 58,478 | 0.00 | 160,678 |
1 Mar 24 | Doug Rice | Stock Options Common Stock | Grant | Acquire A | No | No | 8.63 | 70,755 | 610.62 k | 164,755 |
News
Lake Street Initiates Coverage On MiMedx Group with Buy Rating, Announces Price Target of $12
7 Mar 24
Mizuho Maintains Buy Rating for MiMedx Group: Here's What You Need To Know
1 Mar 24
Mizuho Maintains Buy on MiMedx Group, Raises Price Target to $14
1 Mar 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
28 Feb 24
Earnings Scheduled For February 28, 2024
28 Feb 24
Press releases
MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30
16 Apr 24
MIMEDX Introduces E-Commerce and Account Management Platform
13 Mar 24
MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results
28 Feb 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
30 Jan 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
26 Jan 24